 Dose-Response Relationship, Drug
"Dose-Response Relationship, Drug" is a descriptor in the National Library of Medicine's controlled vocabulary thesaurus,
MeSH (Medical Subject Headings). Descriptors are arranged in a hierarchical structure,
which enables searching at various levels of specificity.
The relationship between the dose of an administered drug and the response of the organism to the drug.
| Descriptor ID |
D004305
|
| MeSH Number(s) |
G07.690.773.875 G07.690.936.500
|
| Concept/Terms |
Dose-Response Relationship, Drug- Dose-Response Relationship, Drug
- Dose-Response Relationships, Drug
- Drug Dose-Response Relationship
- Drug Dose-Response Relationships
- Relationship, Drug Dose-Response
- Relationships, Drug Dose-Response
- Dose Response Relationship, Drug
|
Below are MeSH descriptors whose meaning is more general than "Dose-Response Relationship, Drug".
Below are MeSH descriptors whose meaning is more specific than "Dose-Response Relationship, Drug".
This graph shows the total number of publications written about "Dose-Response Relationship, Drug" by people in this website by year, and whether "Dose-Response Relationship, Drug" was a major or minor topic of these publications.
To see the data from this visualization as text, click here.
| Year | Major Topic | Minor Topic | Total |
|---|
| 1995 | 0 | 21 | 21 | | 1996 | 0 | 19 | 19 | | 1997 | 0 | 28 | 28 | | 1998 | 0 | 19 | 19 | | 1999 | 0 | 24 | 24 | | 2000 | 0 | 32 | 32 | | 2001 | 0 | 44 | 44 | | 2002 | 0 | 49 | 49 | | 2003 | 0 | 61 | 61 | | 2004 | 0 | 66 | 66 | | 2005 | 0 | 62 | 62 | | 2006 | 1 | 57 | 58 | | 2007 | 0 | 67 | 67 | | 2008 | 0 | 84 | 84 | | 2009 | 0 | 64 | 64 | | 2010 | 0 | 62 | 62 | | 2011 | 0 | 59 | 59 | | 2012 | 0 | 67 | 67 | | 2013 | 0 | 53 | 53 | | 2014 | 0 | 77 | 77 | | 2015 | 0 | 65 | 65 | | 2016 | 0 | 58 | 58 | | 2017 | 1 | 64 | 65 | | 2018 | 0 | 47 | 47 | | 2019 | 0 | 44 | 44 | | 2020 | 0 | 33 | 33 | | 2021 | 0 | 20 | 20 | | 2022 | 0 | 5 | 5 | | 2023 | 1 | 3 | 4 | | 2024 | 0 | 13 | 13 | | 2025 | 0 | 8 | 8 |
To return to the timeline, click here.
Below are the most recent publications written about "Dose-Response Relationship, Drug" by people in Profiles.
-
Chalmers JD, Burgel PR, Daley CL, De Soyza A, Haworth CS, Mauger D, Loebinger MR, McShane PJ, Ringshausen FC, Blasi F, Shteinberg M, Mange K, Teper A, Fernandez C, Zambrano M, Fan C, Zhang X, Metersky ML. Phase 3 Trial of the DPP-1 Inhibitor Brensocatib in Bronchiectasis. N Engl J Med. 2025 Apr 24; 392(16):1569-1581.
-
Becker WC, Seal KH, Nelson DB, DeRonne BM, Kats AM, Morasco BJ, Frank JW, Makris UE, Painter JT, Allen KD, Mixon AS, Bohnert A, Reznik TE, Hagedorn HJ, Hammett P, Borsari B, Baxley C, Krebs EE. Buprenorphine, Pain, and Opioid Use in Patients Taking High-Dose Long-Term Opioids: A Randomized Clinical Trial. JAMA Intern Med. 2025 Apr 01; 185(4):372-381.
-
Zhou X, Mould DR, Gore L, Bai X, Gupta N. Optimizing Brentuximab Vedotin Dosing in Pediatric Patients with Advanced Hodgkin Lymphoma: A Population Pharmacokinetic and Exposure-Response Analysis. Clin Pharmacol Ther. 2025 Jun; 117(6):1803-1810.
-
Jutabha P, Kumar V, Anzai N, Rice PJ, Lightner JW, Endou H, Wempe MF. Benzbromarone Analog SAR: Potent hURAT1 (SLC22A12) Inhibitors and Drug Transporter Interaction Studies. Drug Des Devel Ther. 2025; 19:1377-1392.
-
DuBois SG, Ogawa C, Moreno L, Moss? YP, Fischer M, Ryan AL, Vo KT, De Wilde B, Rubio-San-Simon A, Macy ME, Howell L, Shusterman S, Corradini N, Luksch R, Aerts I, Foster JH, Weiss BD, Karthik CP, Yuen E, Avsar E, Park JR, Marachelian A. A phase 1 dose-escalation study of LY3295668 erbumine as monotherapy and in combination with topotecan and cyclophosphamide in children with relapsed/refractory neuroblastoma. Cancer. 2025 Feb 15; 131(4):e35751.
-
Campbell K, Neul JL, Lieberman DN, Berry-Kravis E, Benke TA, Fu C, Percy A, Suter B, Morris D, Carpenter RL, Marsh ED, von Hehn J. A randomized, placebo-controlled, cross-over trial of ketamine in Rett syndrome. J Neurodev Disord. 2025 Jan 24; 17(1):4.
-
O'Malley SS, Miranda R, Book SW, Chun TH, Liss T, Malcolm RJ, Muvvala SB, Padovano HT, Schacht JP, Blackburn B, Diamond I, Ransom J, Ryan ML, Falk DE, Litten RZ. Preliminary effects of oral ANS-6637, an ALDH2 inhibitor, on cue-induced craving, safety and alcohol consumption among adults with alcohol use disorder: a proof-of-concept, randomized, human laboratory trial. Alcohol Alcohol. 2025 Jan 19; 60(2).
-
Mar S, Valeriani M, Steinborn B, Schreiner T, Waubant E, Filippi M, Kotulska K, Mazurkiewicz-Beldzinska M, El Azzouzi B, Lin CJ, Shen YA, Kletzl H, Evershed J, Hogea A, Manlius C, Bonati U, Banwell B. Ocrelizumab dose selection for treatment of pediatric relapsing-remitting multiple sclerosis: results of the OPERETTA I study. J Neurol. 2025 Jan 15; 272(2):137.
-
Tremonti C, Blogg J, Jamshidi N, Harjanto R, Miles N, Ismay C, Page R, Mills L, Buckley N, Perananthan V, Lintzeris N, Haber P. Methadone-Buprenorphine Transfers Using Low Dosing of Buprenorphine: An Open-label, Nonrandomized Clinical Trial. J Addict Med. 2025 Jan-Feb 01; 19(1):75-82.
-
Jastreboff AM, le Roux CW, Stefanski A, Aronne LJ, Halpern B, Wharton S, Wilding JPH, Perreault L, Zhang S, Battula R, Bunck MC, Ahmad NN, Jouravskaya I. Tirzepatide for Obesity Treatment and Diabetes Prevention. N Engl J Med. 2025 Mar 06; 392(10):958-971.
|
People  People who have written about this concept. _
Similar Concepts
People who have written about this concept.
_
Top Journals
Top journals in which articles about this concept have been published.
|